Opko Health, Inc. (OPK) analyst actions
Rating and price-target actions on OPK in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the OPK overview →
2 measured OPK analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform | Press release | +0.01% | +2.27% | |
| OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19 | Press release | +1.25% | -0.83% |
Keep exploring
More OPK: earnings → · SEC filings → · OPK overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cronos Group Inc. - Common Share (CRON) | 230 | +0.27% | 62% |
| Forward Pharma A/S - American Depositary Shares (FWP) | 230 | 0.00% | 37% |
| Veru Inc. (VERU) | 230 | -0.47% | 43% |
| iRadimed Corporation (IRMD) | 229 | +0.10% | 55% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.